‘Excitement and Interest’ as Lp(a) Therapies Inch Closer

Why It Matters

A proven Lp(a)‑lowering therapy would provide the first targeted option to mitigate a major, independent risk factor for atherosclerotic disease, potentially reducing cardiovascular events and expanding the therapeutic arsenal for high‑risk patients.

Key Takeaways

• Pelacarsen reduces Lp(a) ~80% in phase 2, phase 3 readout H2 2026
• siRNA agents olpasiran and lepodisiran achieve up to 95% Lp(a) cut
• Oral muvalaplin shows 80% Lp(a) drop, entering phase 3 MOVE‑Lp(a)
• Gene‑editing approaches CTX310 and VERVE‑301 aim for permanent lipid reduction
• No Lp(a) drugs approved yet; guidelines advise risk‑factor management above 50 mg/dL

Pulse Analysis

Lipoprotein(a), or Lp(a), is a genetically determined lipoprotein that carries a cholesterol‑laden particle and an apolipoprotein(a) chain, conferring a roughly 20‑30% increase in cardiovascular risk independent of LDL cholesterol. Current practice relies on aggressive LDL‑lowering and lifestyle measures, because no therapy directly targets Lp(a). The 2024 American Heart Association/American College of Cardiology guideline only recommends intensified risk‑factor control for patients with Lp(a) levels ≥50 mg/dL, leaving a sizable high‑risk population without a disease‑specific option. This therapeutic gap has spurred a wave of biotech investment and academic collaboration over the past decade.

The most advanced candidate, pelacarsen, is a monthly antisense oligonucleotide that achieved an 80% mean Lp(a) reduction in a phase 2 trial and is now being evaluated in the 8,300‑patient Lp(a)HORIZON study for secondary prevention. Parallel siRNA programs—olpasiran, lepodisiran, and zerlasiran—offer longer dosing intervals and have reported up to 95% Lp(a) knockdown, with phase 2 data suggesting additive LDL benefits. Oral small‑molecule inhibitors such as muvalaplin have entered phase 3, while CETP inhibitor obicetrapib and gene‑editing platforms CTX310 and VERVE‑301 broaden the mechanistic landscape, promising durable lipid modulation beyond conventional therapies.

If any of these agents demonstrate cardiovascular outcome benefit, the market could see the first FDA‑approved Lp(a) therapy within the next two years, creating a multi‑billion‑dollar niche for both established pharma and emerging biotech firms. Clinicians would gain a tool to directly address a residual risk factor, potentially reshaping secondary‑prevention algorithms and prompting earlier screening for elevated Lp(a). Investors are closely watching the HORIZON readout, as positive results would validate the antisense approach and likely accelerate funding for complementary modalities, cementing Lp(a) as a new frontier in lipidology.